Correlation Between Molecular Partners and Design Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Design Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Design Therapeutics.

Diversification Opportunities for Molecular Partners and Design Therapeutics

0.15

Correlation Coefficient

Molecular Partners  Design Therapeutics

Average diversification

The 3 months correlation between Molecular and Design is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Design Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Design Therapeutics

Given the investment horizon of 90 days Molecular Partners is expected to generate 1.96 times less return on investment than Design Therapeutics. In addition to that, Molecular Partners is 1.25 times more volatile than Design Therapeutics. It trades about 0.04 of its total potential returns per unit of risk. Design Therapeutics is currently generating about 0.09 per unit of volatility. If you would invest  473.00  in Design Therapeutics on September 2, 2024 and sell it today you would earn a total of  127.00  from holding Design Therapeutics or generate 26.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Design Therapeutics

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Design Therapeutics

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Design Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, Design Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Molecular Partners and Design Therapeutics

The main advantage of trading using opposite Molecular Partners and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.

The idea behind Molecular Partners AG and Design Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.